An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Praxis Precision Medicines to Participate in Upcoming April Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Praxis Precision Medicines, Inc. (PRAX) will participate in upcoming healthcare conferences in April, including the Needham 23rd Annual Healthcare Conference and the Piper Sandler Spring Biopharma Symposium. The company aims to showcase its genetic insights-driven therapies for CNS disorders.
Positive
None.
Negative
None.
BOSTON, April 05, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will take part in upcoming conferences in April.
Praxis management will participate in a fireside chat at the Needham 23rd Annual Healthcare Conference, taking place virtually on April 8, 2024 at 8:00a.m EDT. A live webcast of the fireside chat will be available through this link, and also available on the “Investors + Media” section of the company’s website www.praxismedicines.com. A replay of the webcast will be available on Praxis’ website for 90 days following the event.
Management will also participate in the Piper Sandler Spring Biopharma Symposium, taking place in Boston, MA on April 16-17, 2024.
About Praxis Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, LinkedIn and Twitter/X.
FAQ
When will Praxis Precision Medicines, Inc. (PRAX) participate in the Needham 23rd Annual Healthcare Conference?
Praxis will participate in a fireside chat at the Needham 23rd Annual Healthcare Conference on April 8, 2024, at 8:00 a.m. EDT.
Where can I watch the live webcast of the fireside chat at the conference?
The live webcast will be available through a link and on the 'Investors + Media' section of Praxis' website, www.praxismedicines.com.
When will the replay of the webcast be available on Praxis' website?
The replay of the webcast will be available on Praxis' website for 90 days following the event.
Which other conference will Praxis Precision Medicines, Inc. (PRAX) participate in April?
Praxis will also participate in the Piper Sandler Spring Biopharma Symposium in Boston, MA on April 16-17, 2024.
praxis precision medicines, inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. its lead product candidates include prax-114, an extrasynaptic-preferring gabaa receptor positive allosteric modulator that is in phase iia clinical trial for the treatment of major depressive disorder and perimenopausal depression; and prax-944, a selective small molecule inhibitor of t-type calcium channels, which is in phase iia clinical trial for the treatment of essential tremor. the company is also developing prax-562, a persistent sodium current blocker that is in phase i clinical trial to treat severe pediatric epilepsy and adult cephalgia; prax-222, an antisense oligonucleotide for patients with gain-of-function (gof) scn2a epilepsy; and kcnt1 program for the treatment of kcnt1 gof epilepsy. it has a cooperation and license agreement with rogcon inc.; a license agreement purdue neuroscience company; and a res